• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Nexstim

9.85 EUR0.00 %24.7, 17.25
5,668 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
0.00 %
-0.51 %
+8.24 %
-25.10 %
-30.63 %
-26.22 %
+188.01 %
+179.83 %
-98.37 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
79.54M EUR
Turnover
30.06K EUR
P/E (adj.) (26e)
78.86
EV/EBIT (adj.) (26e)
64.02
P/B (26e)
7.78
EV/S (26e)
6.08
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
11.00 EUR
Updated
14.05.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 15.05.2026

Latest extensive report

Released: 26.06.2025

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Press releases
ShowingAll content types

Forum discussions
In the context of this turnaround, earnings are actually quite sensitive to growth: Last year, the profit for the financial year was 573 thousand euros The gross margin was 77% The price of a well-equipped diagnostic device is approximately 300 thousand euros The gross margin on ...
7/22/2026, 7:12 AM
by Kyhnykeisari
19
It would probably take selling a good 50 or so machines to reach that. Of course, since we’re at 33 machines now, that doesn’t seem impossible at all.
7/21/2026, 10:19 AM
by Jatast
15
The Synaptican CEO has another podcast out: EDIT: 43:55 So, optimistically or or realistically, depending on how you want to answer the question, what’s the timeline here? 44:25 … we’re racing towards pivotal. It’s a fast pivotal that we’ve discussed with the FDA. I don’t want to...
7/21/2026, 3:49 PM
13
But as I understand it, the gross margin also decreases slightly since Brainlab takes its cut, right? I’m working with the rough (and perhaps cautious) assumption that we are currently at about a break-even level, and that from around these levels, about 150k€ should start dropping...
7/24/2026, 6:45 AM
by Informaatio
11
Yeah, or it could be that they weren’t sold with standard margins. Well, either way, I prefer to focus on the Big Picture, and a couple of machines don’t really affect that. What does matter is whether we’ll surpass last year’s sales figures this year. And whether we might even exceed...
7/21/2026, 6:43 PM
by Informaatio
11
It will happen during the current fiscal year unless a miracle occurs. The profit margins are strong.
7/21/2026, 9:55 AM
by Puutaheinää
11
Brain research is becoming interesting when even private individuals are building $260 million research centers. Fortune A family crisis inspired Bill Ackman to spend $260 million to create a... The new facility will be constructed on the Upper West Side, where Ackman has just purchased...
7/22/2026, 9:46 AM
by Kyhnykeisari
10
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
14.8
2026

Interim report Q2'26

Regulatory press release20.07.2026, 12.00

Nexstim Plc: Disclosure of major holdings under Chapter 9, Section 10 of the Finnish Securities Markets Act

Nexstim
Press release17.07.2026, 08.00

Delve Psychiatry Upgrades to Nexstim's Latest NBS 6 Platform

Nexstim
Press release15.07.2026, 08.00

Nexstim Receives NBS 6 Therapy System Order from a Neurology Clinic in the United States

Nexstim

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Nexstim received another order for ten NBS 6 systems
Analyst Comment15.07.2026, 08.01 by
Frans-Mikael Rostedt

Nexstim received another order for ten NBS 6 systems

The second order for ten systems within a month indicates the rapid scaling of the distribution partnership.

Nexstim
Press release14.07.2026, 08.00

Nexstim Receives a New Order for Ten NBS 6 Systems from Distributor

Nexstim
Press release10.07.2026, 08.00

Nexstim Receives Expanded Health Canada Approval for NBS 6 Diagnostics and Pain Applications

Nexstim
Press release08.07.2026, 08.00

Nexstim Secures First NBS 6 Sale Following Malaysian Market Authorization

Nexstim
Press release07.07.2026, 08.00

Nexstim Receives Malaysian Authorization for Commercial Distribution of NBS System 6

Nexstim
New NBS 6 system order for Nexstim from USA
Analyst Comment06.07.2026, 08.17 by
Atte Riikola

New NBS 6 system order for Nexstim from USA

This is a new customer for the company

Nexstim
Press release03.07.2026, 08.00

Nexstim Receives NBS 6 Therapy System Order from New Customer in the United States

Nexstim
Significant one-time order for Nexstim
Analyst Comment12.06.2026, 08.28 by
Antti Siltanen

Significant one-time order for Nexstim

The one-time order for ten systems strengthens our confidence in this year's growth estimates.

Nexstim
Press release11.06.2026, 08.00

Nexstim Receives Order for Ten NBS 6 Systems from Distributor

Nexstim
Nexstim received a new sales authorization for the NBS 6 system in Australia
Analyst Comment04.06.2026, 07.48 by
Antti Siltanen

Nexstim received a new sales authorization for the NBS 6 system in Australia

The sales authorization expands the use of the NBS 6 system to diagnostics and rehabilitation.

Nexstim
Press release03.06.2026, 09.00

Nexstim granted authorization for commercial distribution of NBS System 6 for use in diagnostics and post-operative rehabilitation in Australia

Nexstim
Regulatory press release25.05.2026, 08.00

Nexstim Plc’s New Shares Have Been Registered with the Finnish Trade Register

Nexstim
Regulatory press release18.05.2026, 16.00

Nexstim Plc: Disclosure of major holdings under Chapter 9, Section 10 of the Finnish Securities Markets Act

Nexstim
Regulatory press release15.05.2026, 13.40

Nexstim Plc: Managers’ Transactions, Järnefelt

Nexstim
Regulatory press release15.05.2026, 13.40

Nexstim Plc: Managers’ Transactions, Hannula

Nexstim
Regulatory press release15.05.2026, 13.40

Nexstim Plc: Managers’ Transactions, Niemistö

Nexstim
Regulatory press release15.05.2026, 13.40

Nexstim Plc: Managers’ Transactions, Laine

Nexstim